The global lentiviral vector CDMO market is projected to grow at a CAGR of 8% over the next five years. This growth is driven by rising demand for gene and cell therapies, an expanding pipeline of ...

Delivery of TPST-2003 lentiviral vector to Cincinnati Children’s Applied Gene and Cell Therapy Center enables manufacturing ...

Eli Lilly is picking up its second in vivo CAR-T company of the year, paying $3.25 billion in upfront cash for Kelonia ...

Eli Lilly will acquire Kelonia Therapeutics for up to $7bn, securing its lentiviral-based in vivo CAR-T platform and oncology pipeline. The move follows Lilly’s $2.4bn purchase of Orna Therapeutics, ...

New expedited service line designed for biotechs with timeline constraints, launched in response to client demandCan accelerate timeline to GMP ...

Challenges include high costs and limited diagnosis, but opportunities for growth lie in gene therapy commercialization, expanded screening, and emerging marketsDublin, April 21, 2026 (GLOBE NEWSWIRE) ...

Lentiviral vectors effectively deliver the gene that encodes coagulation factor IX (FIX) to the liver in dogs with naturally occurring hemophilia B (factor IX deficiency), researchers report in an ...

Lentiviral vectors are one of the foundational technologies of cell and gene therapy. Along with adenoviral vectors, they are one of the most widely used means of introducing genetic information into ...

Cell and gene therapies rely on engineered viruses to deliver them to their cellular destinations. While the progress of these types of medicines is evident in a growing number of FDA product ...

SAN DIEGO -- Results from a small single-center study showed that treatment with a gene therapy involving the use of lentiviral vector-transduced autologous hematopoietic stem cells (HSCs) increased ...

Vector BioMed raised $15 million in a first round of funding as the startup looks to help fill a big gap in the manufacture of cell and gene therapies. The latest entry into the CDMO viral vector ...

Rentschler Biopharma launched an expanded service offering at its dedicated Advanced Therapy Medicinal Products (ATMP) site in Stevenage, U.K. The company introduced a new lentiviral vector ...